For adult patients with moderate to severe chronic plaque psoriasis (Ps)

Sustained skin clearance at 1 year

Many HUMIRA-treated patients maintained skin clearance at week 521-4


STUDY DESIGN INTRODUCTIONS

REVEAL was a 52-week randomized, double-blind, placebo-controlled trial of 1212 adult patients with moderate to severe chronic plaque psoriasis. In Period C, patients who maintained at least a PASI 75 response at week 33 and were originally randomized to HUMIRA 40 mg EOW in Period A were re-randomized to receive HUMIRA 40 mg or placebo EOW for an additional 19 weeks. Proportion of patients losing an adequate response after week 33 and on or before week 52 was also studied.1,2

View full study design

Skin clearance results at week 52 vs placebo

Maintained PASI 75*

% of patients

Achieved PASI 90

% of patients

Achieved PASI 100

% of patients

PGA of clear or minimal§: 68% of HUMIRA-treated patients (n=250) achieved response compared to 28% of patients re-randomized to placebo (n=240, P<0.001).§

HUMIRA 40 mg EOW (n=250)

Placebo (n=240)


*PASI 75 represents a ≥75% improvement in skin clearance from baseline.
PASI 90 represents a ≥90% improvement in skin clearance from baseline.
PASI 100 represents a 100% improvement in skin clearance from baseline.

§PGA of clear defined as no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red coloration. Minimal defined as possible but difficult to ascertain whether there is slight elevation of plaque above normal skin, plus or minus surface dryness with some white coloration, plus or minus up to red coloration.

BSA=body surface area; EOW=every other week; OLE=open-label extension; PASI=Psoriasis Area and Severity Index; PGA=physician’s global assessment